1、 Baptista ResearchBaptista Research01-06-2025AbbVie Inc.(ABBV)Industry View:In-LineStock Rating:HoldPrice Target:$208.0Current Price:$186.1Shares Outstanding:1,766.40 MMAverage Daily Volume(3 months):8.08 MM52-Week High:US$218.6652-Week Low:US$158.83Objective Of The ReportCompany OverviewBaptista Re

2、search looks to evaluate the different factors that could influence the companys price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow(DCF)methodology.In this report,we have carried out a fundamental analysis of the historical financi

3、al statements of the company.We also have a dedicated analysis of the companys Environmental,Social,and Governance(ESG)risk scores in order to evaluate the sustainability risk.We have added reasonable forecasts of the annualized income statement and cash flows and carried out a DCF valuation of the

4、company using its Weighted Average Cost of Capital(WACC)to determine a forecasted share price.We have further incorporated a sensitivity analysis/scenario analysis to understand how changes in key assumptions could impact the valuation under 3 scenarios-a base case,a bull case,and a bear case.These

5、additional layers of analysis serve to provide a comprehensive and robust valuation,giving investors a nuanced understanding of the inherent risks and opportunities.AbbVie Inc.,a research-based biopharmaceutical company,engages in the research and development,manufacture,commercialization,and sale o

6、f medicines and therapies worldwide.The company offers Humira,an injection for autoimmune and intestinal Behets diseases,generalized pustular psoriasis,and pyoderma gangrenosum;Skyrizi to treat autoimmune diseases,erythrodermic psoriasis,generalized pustular psoriasis,and palmoplantar pustulosis;Rin